Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 37 studies | 41% ± 15% | |
classical monocyte | 23 studies | 31% ± 10% | |
non-classical monocyte | 19 studies | 31% ± 10% | |
monocyte | 15 studies | 30% ± 13% | |
endothelial cell of lymphatic vessel | 15 studies | 32% ± 9% | |
conventional dendritic cell | 14 studies | 30% ± 12% | |
myeloid cell | 11 studies | 35% ± 12% | |
plasma cell | 9 studies | 33% ± 9% | |
endothelial cell | 7 studies | 29% ± 8% | |
microglial cell | 7 studies | 28% ± 9% | |
dendritic cell | 7 studies | 31% ± 16% | |
alveolar macrophage | 6 studies | 33% ± 12% | |
neutrophil | 6 studies | 23% ± 7% | |
mononuclear phagocyte | 6 studies | 36% ± 12% | |
endothelial cell of vascular tree | 5 studies | 20% ± 2% | |
plasmacytoid dendritic cell | 5 studies | 25% ± 8% | |
vein endothelial cell | 4 studies | 18% ± 5% | |
leukocyte | 3 studies | 21% ± 3% | |
IgG plasma cell | 3 studies | 21% ± 2% | |
intermediate monocyte | 3 studies | 35% ± 13% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 361.18 | 459 / 459 | 98% | 37.45 | 1095 / 1118 |
lung | 100% | 420.78 | 578 / 578 | 97% | 59.66 | 1126 / 1155 |
ovary | 100% | 303.92 | 180 / 180 | 84% | 23.77 | 362 / 430 |
thymus | 95% | 155.92 | 623 / 653 | 82% | 20.76 | 497 / 605 |
kidney | 91% | 138.53 | 81 / 89 | 85% | 36.62 | 763 / 901 |
uterus | 96% | 184.16 | 164 / 170 | 79% | 23.85 | 361 / 459 |
esophagus | 84% | 121.32 | 1209 / 1445 | 85% | 27.07 | 156 / 183 |
bladder | 100% | 209.19 | 21 / 21 | 68% | 22.16 | 344 / 504 |
skin | 75% | 188.05 | 1348 / 1809 | 92% | 87.95 | 433 / 472 |
adrenal gland | 99% | 253.02 | 255 / 258 | 62% | 31.68 | 142 / 230 |
intestine | 92% | 159.14 | 888 / 966 | 63% | 16.86 | 331 / 527 |
prostate | 87% | 123.96 | 214 / 245 | 59% | 9.62 | 296 / 502 |
stomach | 68% | 91.81 | 245 / 359 | 77% | 28.16 | 219 / 286 |
brain | 53% | 72.62 | 1402 / 2642 | 83% | 37.00 | 585 / 705 |
liver | 58% | 74.35 | 132 / 226 | 76% | 39.92 | 309 / 406 |
pancreas | 28% | 25.80 | 92 / 328 | 91% | 40.16 | 162 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 119.16 | 29 / 29 |
spleen | 100% | 1167.84 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.64 | 1 / 1 |
adipose | 100% | 442.50 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 272.15 | 1302 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 859.64 | 868 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 28.22 | 41 / 45 |
eye | 0% | 0 | 0 / 0 | 84% | 133.60 | 67 / 80 |
heart | 83% | 113.35 | 717 / 861 | 0% | 0 | 0 / 0 |
muscle | 25% | 21.61 | 200 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031663 | Biological process | lipopolysaccharide-mediated signaling pathway |
GO_0002224 | Biological process | toll-like receptor signaling pathway |
GO_0006954 | Biological process | inflammatory response |
GO_0045087 | Biological process | innate immune response |
GO_0031666 | Biological process | positive regulation of lipopolysaccharide-mediated signaling pathway |
GO_0006968 | Biological process | cellular defense response |
GO_0034142 | Biological process | toll-like receptor 4 signaling pathway |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0032497 | Biological process | detection of lipopolysaccharide |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0046696 | Cellular component | lipopolysaccharide receptor complex |
GO_0010008 | Cellular component | endosome membrane |
GO_0015026 | Molecular function | coreceptor activity |
GO_0035662 | Molecular function | Toll-like receptor 4 binding |
GO_0001875 | Molecular function | lipopolysaccharide immune receptor activity |
GO_0001530 | Molecular function | lipopolysaccharide binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LY96 |
Protein name | Lymphocyte antigen 96 (Ly-96) (ESOP-1) (Protein MD-2) MD-2 mimetic protein variant |
Synonyms | ESOP1 MD2 |
Description | FUNCTION: Binds bacterial lipopolysaccharide (LPS) . Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria . Enhances TLR4-dependent activation of NF-kappa-B . Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS . . |
Accessions | D0VAW8 ENST00000518893.1 [Q9Y6Y9-2] ENST00000284818.7 [Q9Y6Y9-1] Q9Y6Y9 |